Retatrutide (Triple GIP/GLP-1/Glucagon Agonist), TRIUMPH
Obesity, obstructive sleep apnoea and type 2 diabetes
Sponsor: Eli Lilly
- 10,000Enrollment target
- N/ATrial sites
- N/ACountries
- February 2029Est. completion
- NCT06383390Registry record
About this trial
Triple-receptor agonist and successor asset to tirzepatide, tested across obesity, sleep apnoea, diabetes and cardiovascular outcomes.
Primary endpoints
- Percentage change in body weight
- Major adverse cardiovascular events
Latest update
Lilly reported that retatrutide succeeded in two further Phase 3 obesity trials, delivering up to 22.6 per cent weight loss and setting up an FDA filing in early 2027. TRIUMPH-1 had earlier shown up to 30.3 per cent average weight loss, announced 21 May 2026, and a separate Phase 3 showed reduced obstructive sleep apnoea severity on 23 June.
SourceTrial information is compiled from public sources and may be out of date. It is not medical advice and is not an offer of enrolment; check the registry entry or speak to a physician before acting on it.